Cancer News and Research

Latest Cancer News and Research

Vorinostat reduces risk of graft-vs.-host disease from bone marrow transplant treatments

A new class of drugs reduced the risk of patients contracting a serious and often deadly side effect of lifesaving bone marrow transplant treatments, according to a study from researchers at the University of Michigan Comprehensive Cancer Center.

10 Dec 2012

Results from eribulin and capecitabine phase III comparison trial on metastatic breast cancer

Results from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate with capecitabine, a standard drug used for chemotherapy today in women with previously treated metastatic breast cancer, showed that eribulin demonstrated a trend toward improved overall survival.

10 Dec 2012

Ipsen, Active Biotech complete enrollment in tasquinimod Phase III trial for prostate cancer

Active Biotech and Ipsen today announced that the Phase III clinical trial for tasquinimod, a novel compound for the treatment of prostate cancer, is successfully enrolled with over 1,200 randomized patients as planned in the clinical protocol.

10 Dec 2012

New survival results from Genentech’s Perjeta Phase III combination study on HER2-positive mBC

Genentech, a member of the Roche Group, today announced updated survival results from the Phase III CLEOPATRA study, which showed that the combination of Perjeta (pertuzumab), Herceptin (trastuzumab) and docetaxel chemotherapy significantly extended the lives (overall survival) of people with previously untreated HER2-positive metastatic breast cancer (mBC), compared to Herceptin, chemotherapy and placebo.

10 Dec 2012

Study examines association between ischemic-hypoxic conditions and ADHD

Children who had in-utero exposure to ischemic-hypoxic conditions, situations during which the brain is deprived of oxygen, were significantly more likely to develop attention deficit hyperactivity disorder later in life as compared to unexposed children, according to a Kaiser Permanente study published in the journal Pediatrics.

10 Dec 2012

Ibrutinib may effectively combat chronic lymphocytic leukemia

The promising investigational targeted therapy ibrutinib and its mechanism of silencing gene communication pathways critical to the development of cancer may be an effective way to combat chronic lymphocytic leukemia (CLL), according to studies presented today at the 54th Annual Meeting of the American Society of Hematology (ASH).

10 Dec 2012

MSKCC establishes new pancreatic cancer research center

A new pancreatic cancer research center has been created at Memorial Sloan-Kettering Cancer Center (MSKCC). The ambitious initiative was established with an initial commitment of $10 million from MSKCC Board member David M. Rubenstein.

10 Dec 2012

Genzyme receives EC approval for Thyrogen product label expansion

Genzyme, a Sanofi company, today announced it has received European Commission approval of a product label expansion for the use of Thyrogen (thyrotropin alfa) with a wider irradiation dose range for postoperative thyroid remnant ablation.

10 Dec 2012

Angiocidin reduces acute myeloid leukemia cells in vivo by almost two-thirds in pre-clinical studies

Angiocidin, a novel tumor-inhibiting protein, has been shown to reduce acute myeloid leukemia (AML) cells in vivo by almost two-thirds in pre-clinical experiments.

10 Dec 2012

Perimenopausal lifestyle modifications could reduce risk of breast cancer in obese woman

Obese women might be able to eliminate their increased risk for postmenopausal breast cancer by taking measures during perimenopause to prevent weight gain and to therapeutically control the metabolic effects of their obesity, according to the results of a preclinical study published in Cancer Research, a journal of the American Association for Cancer Research.

10 Dec 2012

Survey finds heavy use of online physician-only communities

A new survey shows that about one in four physicians uses social media daily or multiple times a day to scan or explore medical information, and 14 percent use social media each day to contribute new information, according to an oncologist at the Johns Hopkins Kimmel Cancer Center.

10 Dec 2012

Mesupron could extend progression-free survival for metastatic breast cancer patients

Previous research has shown that a family of genes, proteins and enzymes called the uPA system (for urokinase plasminogen activator) plays an active role in different facets of cancer's biology, including tumor cell invasion, the spread of metastases, and the growth of a primary tumor. Mesupron- is a new small molecule inhibitor, taken as a pill, that inhibits the uPA system.

10 Dec 2012

Sinai Hospital of Baltimore announces opening of new geriatric surgery center

Sinai Hospital of Baltimore, a LifeBridge Health center, is proud to announce the opening of the Sinai Center for Geriatric Surgery, the nation's first surgical center dedicated exclusively to providing specialized surgical and pre and postoperative care for elderly patients.

10 Dec 2012

Sanofi announces new data from SAR302503 Phase II trial on myelofibrosis

Sanofi announced today new Phase II data showing that treatment with a novel, investigational, selective JAK2 inhibitor (SAR302503) reduced spleen size and improved constitutional symptoms in patients with intermediate-2 or high-risk primary or secondary myelofibrosis (MF), a hematologic malignancy with unmet medical needs.

10 Dec 2012

New 3D culture system mimics environment surrounding inflammatory breast cancer cells

Inflammatory breast cancer (IBC) is a very rare and aggressive disease that progresses rapidly and is associated with a very low survival rate. To understand how this type of cancer spreads, it's crucial to characterize the interactions between cancer cells and their 3D environment.

10 Dec 2012

Targeting RAD52 protein can block the process by which leukemia stem cells repair themselves

Despite treatment with imatinib, a successful drug that targets chronic myeloid leukemia (CML), a deadly type of cancer, some patients may continue to be at risk for relapse because a tiny pool of stem cells is resistant to treatment and may even accumulate additional genetic aberrations, eventually leading to disease progression and relapse. These leukemia stem cells are full of genetic errors, loaded with potentially lethal breaks in DNA, and are in a state of constant self-repair.

10 Dec 2012

Beth Israel Deaconess Medical Center introduces CeliacNow website

It's estimated that one in 100 people in the United States are living with celiac disease, but there are only a handful of celiac centers throughout the country. In response to a growing need for educational materials, clinicians at Beth Israel Deaconess Medical Center's Celiac Center have launched CeliacNow, a nutritional management website designed to maximize the health and wellbeing of people living with celiac disease and other gluten-related disorders.

10 Dec 2012

GSK, MD Anderson partner to develop new therapeutic antibodies against cancer

The University of Texas MD Anderson Cancer Center and GlaxoSmithKline (GSK) have signed a research collaboration and license agreement to develop new therapeutic antibodies that promote an immune system attack against cancer.

10 Dec 2012

Most triple-negative breast cancer patients have multiple genetic mutations after chemo treatment

Most triple-negative breast cancer patients who were treated with chemotherapy to shrink the tumor prior to surgery still had multiple genetic mutations in their tumor cells, according to a study by Vanderbilt-Ingram Cancer Center (VICC) investigators.

10 Dec 2012

Celldex announces final results from CDX-011 Phase 2b study on GPNMB-expressing breast cancer

Celldex Therapeutics, Inc. today announced final results from the Company's randomized Phase 2b EMERGE study of CDX-011 in patients with glycoprotein NMB (GPNMB)-expressing, advanced, heavily pretreated breast cancer.

9 Dec 2012

Cancer News and Research

Latest Cancer News and Research

Vorinostat reduces risk of graft-vs.-host disease from bone marrow transplant treatments

Results from eribulin and capecitabine phase III comparison trial on metastatic breast cancer

Ipsen, Active Biotech complete enrollment in tasquinimod Phase III trial for prostate cancer

New survival results from Genentech’s Perjeta Phase III combination study on HER2-positive mBC

Study examines association between ischemic-hypoxic conditions and ADHD

Ibrutinib may effectively combat chronic lymphocytic leukemia

MSKCC establishes new pancreatic cancer research center

Genzyme receives EC approval for Thyrogen product label expansion

Angiocidin reduces acute myeloid leukemia cells in vivo by almost two-thirds in pre-clinical studies

Perimenopausal lifestyle modifications could reduce risk of breast cancer in obese woman

Survey finds heavy use of online physician-only communities

Mesupron could extend progression-free survival for metastatic breast cancer patients

Sinai Hospital of Baltimore announces opening of new geriatric surgery center

Sanofi announces new data from SAR302503 Phase II trial on myelofibrosis

New 3D culture system mimics environment surrounding inflammatory breast cancer cells

Targeting RAD52 protein can block the process by which leukemia stem cells repair themselves

Beth Israel Deaconess Medical Center introduces CeliacNow website

GSK, MD Anderson partner to develop new therapeutic antibodies against cancer

Most triple-negative breast cancer patients have multiple genetic mutations after chemo treatment

Celldex announces final results from CDX-011 Phase 2b study on GPNMB-expressing breast cancer

Cancer Research - Second Edition eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in